BlinkLab Partners With SHANK2 Foundation For Research
-1200x645.jpg)
BlinkLab (ASX: BB1) has entered a partnership with the US-based SHANK2 Foundation to support advocacy, build research infrastructure, collect data, and conduct phenotyping studies on SHANK2-related neurodevelopmental disorders. The collaboration gives BlinkLab access to genetically confirmed patient cohorts to externally validate its smartphone-based diagnostic platform BlinkLab Dx 1 using AI-driven neurometric assessments and includes planned mouse-model testing via the SCANNER consortium.
Key Points
- 1Establishes BlinkLab partnership with SHANK2 Foundation for phenotyping and data collection on SHANK2 disorders
- 2Provides genetically defined cohorts enabling stronger validation of digital biomarkers and precise digital phenotyping
- 3Enables BlinkLab to validate BlinkLab Dx 1 performance and support rare-disease research and trials
Scoring Rationale
Strong research relevance and actionable validation opportunity, limited novelty as a targeted corporate partnership with modest industry impact.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
